NIH to Study Allergic Reactions Linked to COVID-19 Shots
The National Institutes of Health plans to begin a clinical trial that aims to help doctors “predict and manage” allergic reactions related to Pfizer Inc.’s COVID-19 vaccine.
Moncef Slaoui, chief scientific adviser to Operation Warp Speed, said during a Monday news briefing that the aim of the trial, which will also study the Moderna Inc. shot just authorized for emergency use, will be to pinpoint why the incidents, known as anaphylaxis, are occurring.
During the briefing, Slaoui also addressed a new variant of the virus seen in the U.K., saying it’s no more dangerous than other strains and that there is “no hard evidence” it is more transmissible. Getting the data to determine that, he said, will take weeks.
The emergence of the allergic reactions, even in just a handful of cases, and questions surrounding the U.K. mutation have opened new concerns worldwide about the virus. France, Germany, Italy and other countries have already gone as far as blocking travel from the U.K. after the variant was identified.
“It’s clear, it’s not more pathogenic” than other strains of the SARS-CoV-2 virus, Slaoui said. He also said he expects the existing vaccines will likely still offer protection against it.
To date, he said, “there is no hard evidence that this virus is actually more transmissible.” The virus may have been “seeded” more widely in the southeast England area where it’s now being detected with greater frequency.
The NIH study on reactions to the Pfizer vaccine will test the shots “in highly allergic individuals,” Slaoui said. Both the Pfizer and Moderna shots — which are based on similar messenger RNA technology — will be studied, he said.
Both vaccines authorized for emergency use in the U.S. have been ruled generally safe, and both were found to be better than 90% effective in late-stage trials. Side effects noted have included headaches and fatigue, but they have ended within a couple of days.
©2020 Bloomberg L.P.
Distributed by Tribune Content Agency, LLC
In The News
WASHINGTON — This week, U.S. Reps. Ron Kind, D-Wis., and Mike Gallagher, R-Wis., sent a bipartisan letter to Operation Warp Speed leadership urging them to consider the unique challenges of vaccine distribution to rural areas across Wisconsin and take steps to support timely and equitable vaccine... Read More
The rapid expansion of COVID-19 vaccinations to senior citizens across the U.S. has led to bottlenecks, system crashes and hard feelings in many states because of overwhelming demand for the shots. Mississippi's Health Department stopped taking new appointments the same day it began accepting them because... Read More
WILMINGTON, Del. - President-elect Joe Biden on Thursday night unveiled a $1.9 trillion COVID-19 relief plan intended to aid struggling Americans and businesses, bolster state and local governments, and dramatically ramp up the distribution of the coronavirus vaccine with a goal of reaching 100 million doses... Read More
WUHAN, China (AP) — The WHO team of international researchers that arrived in the central Chinese city of Wuhan on Thursday hopes to find clues to the origin of the COVID-19 pandemic. The visit has been shrouded in secrecy, with neither China nor the WHO revealing... Read More
WASHINGTON - The U.S. Supreme Court lifted a nationwide injunction Tuesday that had prevented the federal government from enforcing a rule that required women to see a health care professional in person before she'd be given access to a so-called abortion pill. The Food and Drug... Read More
WASHINGTON - Reps. Debbie Dingell, D-Mich., and Anthony Brown, D-Md., are tired of colleagues who refuse to wear a face mask to slow the spread of the coronavirus. Now, they are urging the House to impose a $1,000 a day fine on any member of Congress... Read More